P279. Safety and Tolerability Profile of Zuranolone From the LANDSCAPE (Major Depressive Disorder) and NEST (Postpartum Depression) Clinical Development Programs

Abstract

Zuranolone is an investigational, rapidly acting, oral neuroactive steroid and GABA type A receptor positive allosteric modulator in clinical development for once-daily, 2-week treatment of major depressive disorder (MDD) and postpartum depression (PPD). Here, we summarize safety data from 4 completed placebo-controlled trials in the zuranolone clinical development program.